<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) contributes to the development of several human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> including the endemic form of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In culture, EBV induces the continuous proliferation of primary B cells as lymphoblastoid cell lines (LCLs) and if EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-derived cells are infected with EBV, latency-associated <z:mp ids='MP_0001799'>viral</z:mp> factors confer resistance to various inducers of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>Nuclear proteins EBNA3A and EBNA3C (but not EBNA3B) are necessary to establish LCLs and their expression may be involved in the resistance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells to cytotoxic agents </plain></SENT>
<SENT sid="3" pm="."><plain>We have therefore created recombinant EBVs from which each of the EBNA3 genes has been independently deleted, and <z:mp ids='MP_0003171'>revertant</z:mp> viruses in which the genes have been re-introduced into the <z:mp ids='MP_0001799'>viral</z:mp> genome </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of EBV-negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells with this panel of EBVs and challenge with various cytotoxic drugs showed that EBNA3A and EBNA3C cooperate as the main determinants of both drug resistance and the downregulation of the proapoptotic Bcl-2-family member Bcl-2-interacting mediator of cell <z:hpo ids='HP_0011420'>death</z:hpo> (<z:chebi fb="3" ids="33173">Bim</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>The regulation of <z:chebi fb="3" ids="33173">Bim</z:chebi> is predominantly at the level of <z:chebi fb="40" ids="33697">RNA</z:chebi>, with little evidence of post-translational <z:chebi fb="3" ids="33173">Bim</z:chebi> stabilization by EBV </plain></SENT>
<SENT sid="6" pm="."><plain>In the absence of <z:chebi fb="3" ids="33173">Bim</z:chebi>, EBNA3A and EBNA3C appear to provide no survival advantage </plain></SENT>
<SENT sid="7" pm="."><plain>The level of <z:chebi fb="3" ids="33173">Bim</z:chebi> is a critical regulator of B cell survival and reduced expression is a major determinant of <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> in mice and humans; moreover, <z:chebi fb="3" ids="33173">Bim</z:chebi> is uniquely important in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>By targeting this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-suppressor for repression, EBV significantly increases the likelihood of B <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> in general, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in particular </plain></SENT>
<SENT sid="9" pm="."><plain>Our results may also explain the selection pressure that gives rise to a subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> that retain expression of the EBNA3 proteins </plain></SENT>
</text></document>